---
schema_version: "secwatch.filing_event.v1"
accession: "0001827635-26-000023"
form_type: "8-K"
ticker: "MANE"
cik: "0001827635"
company_name: "Veradermics, Inc"
filed_at: "2026-07-15T12:54:36+00:00"
generated_at: "2026-07-15T13:00:11.919645+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Veradermics: Phase 2 VDPHL01 shows 22.7-23.3 hairs/cm² increase, 88.9-90% improved at Month 6

## Summary
- Mean non-vellus hair count increase of 22.7 hairs/cm² (once daily) and 23.3 hairs/cm² (twice daily) at Month 6.
- 88.9% (once daily) and 90.0% (twice daily) of patients reported 'improved' or 'much improved' on AAIRS at Month 6.
- Fast onset: 67.2% of participants graded by investigators as improved at Month 2, earliest measured time point.
- No treatment-related SAEs or cardiac AESIs; common AEs were hypertrichosis and peripheral edema.
- Topline results from Phase 2/3 Study '306' in female pattern hair loss expected in 1H 2027.

## SEC filing metadata
- accession: 0001827635-26-000023
- form_type: 8-K
- ticker: MANE
- cik: 0001827635
- company_name: Veradermics, Inc
- filed_at: 2026-07-15T12:54:36+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1827635/000182763526000023/0001827635-26-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1827635/000182763526000023/mane-20260715.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001827635-26-000023
- JSON: https://secwatch.observer/filing/0001827635-26-000023.json
- Plain text: https://secwatch.observer/filing/0001827635-26-000023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.